Choose Your Country or Region

Adezmapimod (SB203580)

Name: Adezmapimod (SB203580)
Brand: Selleck Chemicals
SKU: S1076
Rating: 5 (782 reviews)

Catalog No.S1076 Synonyms: RWJ 64809, PB 203580

For research use only.

Adezmapimod (SB203580, RWJ 64809, PB 203580) is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM in THP-1 cells, 10-fold less sensitive to SAPK3(106T) and SAPK4(106T) and blocks PKB phosphorylation with IC50 of 3-5 μM. SB203580 induces mitophagy and autophagy.

Adezmapimod (SB203580) Chemical Structure

CAS No. 152121-47-6

Selleck's Adezmapimod (SB203580) has been cited by 782 publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Related Compound Libraries

Other p38 MAPK Products

Pexmetinib (ARRY-614)^New

Pexmetinib (ARRY-614) is a potent, orally bioavailable, dual p38 MAPK/Tie-2 inhibitor with IC50 of 4 nM/18 nM in a HEK-293 cell line. Phase 1.
SB239063^New

SB239063 is a potent and selective p38 MAPKα/β inhibitor with IC50 of 44 nM, showing no activity against the γ- and δ-kinase isoforms.
Ravoxertinib (GDC-0994)^New

Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.
Doramapimod (BIRB 796)

Doramapimod (BIRB 796) is a pan-p38 MAPK inhibitor with IC50 of 38 nM, 65 nM, 200 nM and 520 nM for p38α/β/γ/δ in cell-free assays, and binds p38α with K_d of 0.1 nM in THP-1 cells, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2.
SB202190 (FHPI)

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1. SB202190 significantly suppresses Erastin‐dependent ferroptosis.
Ralimetinib (LY2228820) dimesylate

Ralimetinib (LY2228820) dimesylate is a novel and potent inhibitor of p38 MAPK with IC50 of 7 nM in a cell-free assay, does not alter p38 MAPK activation. Phase 1/2.
Losmapimod (GW856553X)

Losmapimod (GW856553X, GW856553, GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pK_i of 8.1 and 7.6 for p38α and p38β, respectively. P38 MAPKs are involved in cell differentiation, apoptosis and autophagy. Phase 3.
PH-797804

PH-797804 is a novel pyridinone inhibitor of p38α with IC50 of 26 nM in a cell-free assay; 4-fold more selective versus p38β and does not inhibit JNK2. Phase 2.
VX-702

VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2.
TAK-715

TAK-715 is a p38 MAPK inhibitor for p38α with IC50 of 7.1 nM, 28-fold more selective for p38α over p38β, no inhibition to p38γ/δ, JNK1, ERK1, IKKβ, MEKK1 or TAK1. Phase 2.

Download Inhibitor Catalog

p38 MAPK Signaling Pathway Map

Biological Activity

Description

Features

First reported p38 inhibitor.

Targets

p38 MAPK ^[1] (THP-1 cells)	PKB ^[1] (THP-1 cells)
0.3 μM-0.5 μM	3 μM-5 μM

In vitro

SB203580 inhibits the IL-2-induced proliferation of primary human T cells, murine CT6 T cells, or BAF F7 B cells with an IC50 of 3–5 μm. SB203580 also inhibits IL-2-induced p70S6 kinase activation, although the concentration required is slightly higher with an IC50 above 10 μm. SB203580 also inhibits the activity of PDK1 in a dose-dependent manner with an IC50 in the 3–10 μm range. ^[1] SB203580 inhibits p38-MAPK stimulation of MAPKAPK2 with an IC50 of approximately 0.07 μM, whereas inhibits total SAPK/JNK activity with an IC50 of 3–10 μM. SB203580 at higher concentrations activates the ERK pathway, which subsequently enhances NF-κB transcriptional activity. ^[2] SB203580 induces autophagy in human hepatocellular carcinoma (HCC) cells. ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

PC12	M3v1bmtqdmG\|ZTDBd5NigQ>?	M{LkWlExKM7:TR?=	MnmxNVUhdWmw		NWjEWXk3UW6qaXLpeJMheDN6IF3BVEBscW6jc3Wge4l1cCCLQ{WwJI9nKDBwNjFOwG0>	NXnlUmIyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{e1NFU4Pyd-N{e1NFU4PzxxYU6=
THP-1	NIDUT2dHfW6ldHnvckBCe3OjeR?=				NUfaPVdXUW6qaXLpeJMhVFCVLXnu[JVk\WRiVF7GZYxxcGFicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zNjFOwG0>	NHXJVHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEOyOVc3QCd-MUizNlU4Pjh:L3G+
PBMC	MUTGeY5kfGmxbjDBd5NigQ>?		NILwSGcyPSCvaX6=	MoXESG1UVw>?	M3fRfmlvcGmkaYTzJJRp\SC{ZXzlZZNmKG:oIHnueIVzdGW3a3nuMVEu[mW2YTD3bZRpKEmFNUCgc4YhOC5yM{eg{txO	NEnTXGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkO2NVM6Pid-MUKzOlE{QTZ:L3G+
SW1353	M163PGZ2dmO2aX;uJGF{e2G7		MkHjNUBp	MlzaSG1UVw>?	NHr5SXRKdmirYnn0d{BKVC14IIDyc4R2[3Srb36ge4l1cCCLQ{WwJI9nKDBwMEWg{txO	NHjiNIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUG0NFc1OSd-MUGxOFA4PDF:L3G+
Hela	MkHoSpVv[3Srb36gRZN{[Xl?			NIH2VGRFVVOR	MkfOTY5pcWKrdIOgWIF1NWmwZIXj[YQhUEmYMTDMWHIhfHKjboPhZ5RqfmG2aX;uJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR\|UxKG:oIECuNUDPxE1?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl{NkexNUc,OTh7Mk[3NVE9N2F-
PC12	M{TBRWZ2dmO2aX;uJGF{e2G7	NV\B[IROOTBizszN		M3XqOmROW09?	NFXuUlFC[3SrdnH0[ZMhVnKoMj;BVmUhcW5icnH0JHBEOTJiY3XscJMh[XO\|ZYPz[YQh[XNiSF:tNUBxem:2ZXnuJIlv\HWldHnvci=>	NFvGd4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
RAW 264.7	NEWwU21EgXSxdH;4bYMhSXO\|YYm=	NWDvcoN1OTJwNTFOwG0>	NEP2U\|IyOmh?	NHfIS4xFVVOR	MWfCcI9kc3NibHX0bIFtKHSxeHnuMY1m\GmjdHXkJIN6fG:2b4jpZ4l1gQ>?	M2LMTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NEi1OVA1Lz5zN{S4OVUxPDxxYU6=
HCA2	MlnmSpVv[3Srb36gRZN{[Xl?	NEnkTYozNjVizszN			NX3WRndKUW6qaXLpeJMheDN6IH3l[IlifGWmIF3LNkBi[3SrdnH0bY9v	NGXLZnY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m2OFc5OCd-MUe5OlQ4QDB:L3G+
U937	NEDqbnJHfW6ldHnvckBCe3OjeR?=				MlH1TY5pcWKrdIOgTmFMNW2nZHnheIVlKGmwdHXy[oVzd25vZ3HtcYEw[W6rc3;tfYNqdi2rbnT1Z4VlKFO2YYSxJJBpd3OyaH;yfYxifGmxbh?=	NFX0e4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEG1O\|EzOid-MUixOVcyOjJ:L3G+
U937	M{XGZ2Z2dmO2aX;uJGF{e2G7				MVLJcohq[mm2czDKRWsudWWmaXH0[YQhcW62ZYLm[ZJwdi2pYX3tZU9idmm\|b335Z4lvNWmwZIXj[YQheDN6IIDoc5NxcG:{eXzheIlwdg>?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDF3N{GyNkc,OThzNUexNlI9N2F-
hESCs	M2\POGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojlOUDPxE1?		M3qwS2ROW09?	NVrTbmVQUW6mdXPld{Bk[XKmaX;tfY9o\W6rYzDhZ5Rqfmm2eTDhd5Nme3OnZDDhd{Bk\WyuIHfyc5d1cA>?	NEizW3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNlM6QSd-MkO2NFI{QTl:L3G+
RAW264.7	MonDSpVv[3Srb36gRZN{[Xl?	Mn3PNVAh\|ryP			M2DCVmlv\HWlZYOgZY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDifUBqdmirYnn0bY5oKEmOLUJOtkBz\WynYYPl	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MUC3PEc,OjN5OUGwO\|g9N2F-
RAW264.7	MlLrSpVv[3Srb36gRZN{[Xl?	MVyxNEDPxE1?			MVfJcoR2[2W\|IHHueIlqdm[uYX3tZZRwenliYXP0bZZqfHliYomgbY5pcWKrdHnu[{BqVk:VIILlcIVie2V?	M3\sSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{mxNFc5Lz5{M{e5NVA4QDxxYU6=
RAW264.7	NHr0WJdHfW6ldHnvckBCe3OjeR?=	M4HXblExKM7:TR?=			MYXJcoR2[2W\|IHHueIlqdm[uYX3tZZRwenliYXP0bZZqfHliYomgbY5pcWKrdHnu[{BPVyC{ZXzlZZNm	M3jOd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{mxNFc5Lz5{M{e5NVA4QDxxYU6=
RAW264.7	MkLJSpVv[3Srb36gRZN{[Xl?	MkX3NVAh\|ryP			M2PjUmlvcGmkaYTzJGxRWy2rbnT1Z4VlKHB\|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=>	NWfrOHJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVYxPTdpPkK0NFE3ODV5PD;hQi=>
IEC-18	MnPOSpVv[3Srb36gRZN{[Xl?	NFixTlUyOCEQvF2=			NHu4VZVKdmirYnn0d{BNWFNvaX7keYNm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44>	NYjC[W9nRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3OVgyOTBpPkKzO\|U5OTFyPD;hQi=>
Sf9	NYnIW4ZjTnWwY4Tpc44h[XO\|YYm=		Mn3tN\|AhdWmwcx?=		MUnJcohq[mm2aX;uJI9nKG[3bHytcIVv\3SqIF\MRWcuPkircz3USXYhfGGpZ3XkJIh2dWGwIGLJVFIh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iYYX0c5Bpd3OyaH;yfYxifGmxbjDwdoUucW6ldXLheIVlKG[xcjCzNEBucW6\|IH\vcIxwf2WmIHL5JIlv[3WkYYTpc44hf2m2aDDBWHAh\m:{IEKgbJJ{KGK7IFHEVE1IdG9iYYPzZZktKEmFNUCgQUAxNjBzIN88UU4>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3NU[1OEc,OjZ2NUW2OVQ9N2F-
sf21	NGrpUGZHfW6ldHnvckBie3OjeR?=				M3LIUWJqdmSrbnegZYZncW6rdImgeI8hf2muZDD0fZBmKGi3bXHuJIJqd3SrbjDsZYJmdGynZDDwN\|gh[WyyaHGgLFkhfG9iM{WyJJJme2mmdXXzLUBmgHC{ZYPz[YQhcW5ic3[yNUBqdnOnY4SgZ4VtdHNiU2DSJIFv[Wy7c3nzMEBM\CB;IECuNFIyPyEQvF2u	Mm\WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6M{S0N\|EoRjJ6OEO0OFMyRC:jPh?=
PBMC	M130RWZ2dmO2aX;uJIF{e2G7				NYO1TIVDUW6qaXLpeIlwdiCxZjDUUmYu[WyyaHGgdJJw\HWldHnvckBjgSCuaYDvdI9tgXOjY3PoZZJq\GVvc4TpcZVt[XSnZDDoeY1idiCyZYLpdIhmemGuIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{NCCLQ{WwJF0hOC5yMkWg{txONg>?	NITOUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi97OEezO\|MxLz57OEezO\|MxRC:jPh?=
PBMC	M3niOmZ2dmO2aX;uJIF{e2G7				MWDJcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRJM06ILXHsdIh{KHC{b3T1Z5Rqd25iYomgbJVu[W5icHXybZBp\XKjbDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyBqUFLNR5MqNCCLQ{WwJF0hOC5yMkWg{txONg>?	NYrNU\|hVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
PBMC	MY\GeY5kfGmxbjDhd5NigQ>?				MVPJcohq[mm2aX;uJI9nKHB\|ODDNRXAhc2mwYYPlJJJmdGG2ZXSgWG5HNWGucHjhJJJmdGWjc3Wg[pJwdSCyZYLpdIhmemGuIHLsc49lKG2xbn;ueYNt\WG{IHPlcIx{KCiSQl3DLUwhUUN3MDC9JFAvODN5IN88UU4>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjB4MUi3Okc,OTJyNkG4O\|Y9N2F-
PBMC	Mm\NSpVv[3Srb36gZZN{[Xl?				MUHJcohq[mm2aX;uJI9nKEySUz3pcoR2[2WmIFnMNU1j\XSjIIDyc4R2[3Srb36gbY4hcHWvYX6gdIVzcXCqZYLhcEBjdG:xZDDtc45wdnWlbHXhdkBk\WyuczjQRm1EeyluIFnDOVAhRSByLkC0PEDPxE1w	NVq0VppXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUe4OFA6Oyd-OUe4OFA6OzxxYU6=
SW1353	MnTuSpVv[3Srb36gZZN{[Xl?				NVntdFVQS2:vcH;1coQhf2G\|IHX2ZYx2[XSnZDDmc5IhcXS\|IHHibYxqfHlidH:gbY5pcWKrdDDJUE03KHC{b3T1Z5Rqd25iaX6gV3cyOzV\|IHPlcIx{KHS{ZXH0[YQhf2m2aDDjfZRwc2mwZYOgTWwuOSCjbnSgWG5HNCCLQ{WwJF0hOC5yNTFOwG0v	NUnRNIE6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC5PVk1PjdpPkGwPVk6PDZ5PD;hQi=>
SW1353	NWLVfoZpTnWwY4Tpc44h[XO\|YYm=				NHnzS5FKdmirYnn0bY9vKG:oIGTOSkBidmRiSVytNUBqdmS3Y3XkJGlNNTZicILv[JVkfGmxbjDpckBpfW2jbjDjbI9v\HKxLYPhdoNwdWFiU2egNVM2OyClZXzsd{whUUN3MDC9JFAvODVizszNMi=>	Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB7OUm0OlgoRjFyOUm5OFY5RC:jPh?=
THP1	MYLGeY5kfGmxbjDhd5NigQ>?				MljHTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBKVDFicILv[JVkfGmxbjDpckBpfW2jbjDUTHAyKGOnbHzzMEBKSzVyIE2gNE4xPSEQvF2u	M{mzeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MEe3N\|Y{Lz5zOEC3O\|M3OzxxYU6=
THP1	MX\GeY5kfGmxbjDhd5NigQ>?				MV7Jcohq[mm2aX;uJI9nKEySUz3zeIlufWyjdHXkJHRPTmGucHjhJJBzd2S3Y4Tpc44hcW5iaIXtZY4hXEiSMTDj[YxteyxiSVO1NEA:KDBwMEWg{txONg>?	NGjTW209[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEC3O\|M3Oyd-MUiwO\|c{PjN:L3G+
THP1	M1PzVmZ2dmO2aX;uJIF{e2G7				NHv4b4dKdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJJR2dW:{IH7lZ5Jwe2m\|IH\hZ5Rwei2jbIDoZUApXE6ILXHsdIhiMSCycn;keYN1cW:wIHnuJHRJWC1zIHPlcIx{NCCHQ{WwJF0hOC5yNjFOwG0v	M4W0OlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MEi2OFg2Lz5zMkC4OlQ5PTxxYU6=
THP1	MoDrSpVv[3Srb36gZZN{[Xl?				NGTuZ2tKdmirYnn0bY9vKG:oIIT1cY9zKG6nY4Lvd4l{KG[jY4TvdkBidHCqYTDy[Yxm[XOnIHL5JHRJWC1zIHPlcIx{NCCLQ{WwJF0hOC5yNzFOwG0v	M1joSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NkW4PFU2Lz5zNU[1PFg2PTxxYU6=
monocytic cell	MWTGeY5kfGmxbjDhd5NigQ>?				NXLWUm1VUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KFSQRj3hcJBp[SCycn;keYN1cW:wIIXzbY5oKGyrcH;wc4x6e2GlY3jhdoll\SC\|dHnteYxifGWmIHj1cYFvKG2xbn;jfZRq[yClZXzsd{whUUN3MDC9JFAvODd{IN88UU4>	NUfvXHZ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK3Nlk3OzdpPkGyO\|I6PjN5PD;hQi=>
THP1	MUHGeY5kfGmxbjDhd5NigQ>?				M1foRWlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBNWFNvc4TpcZVt[XSnZDDUUmYu[WyyaHGgdJJw\HWldHnvckBqdiCqdX3hckBud26xY4n0bYMh[2WubIOgLHRJWC1zKTygTWM2OCB;IECuNFczKM7:TT6=	NHzlVpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUGzPVc1QSd-MUWxN\|k4PDl:L3G+
THP-1	NH\0ZlNHfW6ldHnvckBie3OjeR?=				MVjJcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgcIlxd3CxbInzZYNkcGG{aXTlJJN1cW23bHH0[YQhXE6ILXHsdIhiKHC{b3T1Z5Rqd25iaX6gWGhRNTFiY3XscJMhMGi3bXHuJI1wdm:leYTpZ{Bk\WyuczmsJGlEPTBiPTCwMlA4OiEQvF2u	NWjyb3U1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4N\|c{OTBpPkG1PFM4OzFyPD;hQi=>
THP1	M{nKfmZ2dmO2aX;uJIF{e2G7				NUX5bYtGUW6qaXLpeIlwdiCxZjDMVHMue3SrbYXsZZRm\CCWTl\hcJBp[SCycn;keYN1cW:wIHnuJHRJWDFiY3XscJMtKEmFNUCgQUAxNjB5MjFOwG0v	M{O5OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{WwN\|Y4Lz5zNke1NFM3PzxxYU6=
PBMC	M3qxXmZ2dmO2aX;uJIF{e2G7				M{PvZmlvcGmkaYTpc44hd2Zic4ThdIh6dG:lb3PjZYwh\W62ZYLveI95cW5iQjjTSWIqKHO2aX31cIF1\WRidIXtc5IhdmWlcn;zbZMh\mGldH;yJIFteGijIDjUUmYu[WyyaHGpJJBzd2S3Y4Tpc44h[nliaIXtZY4heGW{aYDo[ZJidCCkbH;v[EBud26xboXjcIVieiClZXzsd{hRSk2FczmsJGlEPTBiPTCwMlE3KM7:TT6=	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86Pzh2MEmzK\|46Pzh2MEmzQE9iRg>?
PBMC	MWjGeY5kfGmxbjDhd5NigQ>?				NGDofo1Ed26lZX70doF1cW:wIILldZVqemWmIITvJIlvcGmkaYSgcIlxd3CxbInzZYNkcGG{aXTlJIlv\HWlZXSgWG5HNWGucHjhJJJmdGWjc3Wge4F{KGSndHXycYlv\WRiaX6gbJVu[W5icHXybZBp\XKjbDDicI9w\CCvb37vcpVkdGWjcjDj[YxteyxiSVO1NEA:KDBwMUmg{txONg>?	MkP2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV2NUSyN\|EoRjF3NEW0NlMyRC:jPh?=
Sf9	M2nUUGZ2dmO2aX;uJIF{e2G7				NYS4RYZLUW6qaXLpeIlwdiCxZjDmeYxtNWynbnf0bEBHVEGJLU\IbZMuXEWYIITh[4dm\CCqdX3hckBTUVB{IHX4dJJme3OnZDDpckBU\jliY3XscJMh[nliZnz1c5Jme2OnboSgdI9t[XKrenH0bY9vKGG\|c3H5MEBKSzVyIE2gNE4zKM7:TT6=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR3NU[1OEc,OjZ2NUW2OVQ9N2F-
HEK293F	NGfuOpdHfW6ldHnvckBie3OjeR?=				NGDCR49KdmirYnn0bY9vKG:oIIPv[Il2dSCjcoPlcoF1\SCjY4TpeoF1\WRiTj30[ZJucW6jbDDHV3QufGGpZ3XkJGJzfWerYTDtZYxigWliTWDLNUBmgHC{ZYPz[YQhcW5iSFXLNlk{TiClZXzsd{B2e2mwZzDGRW0ueDN6dHnk[UBieyC\|dXLzeJJifGViYomgTW1CWCCjc4PhfUwhUUN3MDC9JFAvOjJizszNMi=>	M{OzO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN\|YzLz5{OUW0NVM3OjxxYU6=
HEK-293	MVzGeY5kfGmxbjDhd5NigQ>?				M4TWW2lvcGmkaYTpc44hd2ZiUlnQNmshcW5iTVTQMZN1cW23bHH0[YQhUEWNLUK5N{Bk\WyuczDveoVzNWW6cILld5NqdmdiTl;ENkBie3Onc4Pl[EBieyCLTEigd4VkemW2aX;uMEBKSzVyIE2gNE4zPSEQvF2u	M{e2ZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUC5PFY4Lz5{N{GwPVg3PzxxYU6=
whole blood cell	M2js[2Z2dmO2aX;uJIF{e2G7	MVmwMlAyKHSxIEGwNEB2VQ>?			MUnJcohq[mm2aX;uJI9nKHB\|OD3y[YxifGWmIFnMNU1j\XSjIILlcIVie2ViYomge4hwdGViYnzvc4Qh[2WubIOgZZQhOTBiZT20JJRwKDFyIHWtPEBONCCLQ{WwJF0hOC5\|NTFOwG0v	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjh3Mke1OEc,OTJ6NUK3OVQ9N2F-
PBMC	MUTGeY5kfGmxbjDhd5NigQ>?				NFu5OmdKdmirYnn0bY9vKG:oIICzPEBOSVBia3nuZZNmKHKnbHH0[YQhXE6ILXHsdIhiKHKnbHXhd4Uh\nKxbTDw[ZJqeGincnHsJIJtd2:mIH3vco9vfWOuZXHyJINmdGy\|IDjQRm1EMSxiSVO1NEA:KDBwNUmg{txONg>?	NFfuUmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkC2NVg4Pid-MUKwOlE5PzZ:L3G+
PBMC	NGjzS2tHfW6ldHnvckBie3OjeR?=				MYLJcohq[mm2aX;uJI9nKHSqZTDy[Yxm[XOnIH;mJJR2dW:{IH7lZ5Jwe2m\|IH\hZ5RweiCjbIDoZUBnem:vIIDldolxcGW{YXygZoxwd2RibX;uc452[2ynYYKgZ4VtdHNuIFnDOVAhRSByLkW5JO69VS5?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjN4MUO5Okc,OTJ\|NkGzPVY9N2F-
PBMC	M{XJcmZ2dmO2aX;uJIF{e2G7				MV;Jcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgWG5HNWGucHjhJJJmdGWjc3WgbY4hWEKPIHPlcIx{NCCLQ{WwJF0hOC53OTFOwG0v	M1f3flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{OEWyO\|U1Lz5zMki1Nlc2PDxxYU6=
whole blood cell	NFr0ZWhHfW6ldHnvckBie3OjeR?=	NWK2cplPOC5yMTD0c{AyODBidV2=			M3LDeGlvcGmkaYTpc44hd2ZicEO4MZJmdGG2ZXSgWG5HNWGucHjhJJJmdGWjc3WgZpkhf2ixbHWgZoxwd2RiY3XscJMh[XRiMUCg[U01KHSxIEGwJIUuQCCPLDDJR\|UxKD1iMD65OEDPxE1w	NYPoUodORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUK4OVI4PTRpPkGyPFUzPzV2PD;hQi=>
BMDC	M2jsUGFvfGmrbn\sZY1u[XSxcomgZZN{[Xl?		MVSxJIhz		MmLvRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBEPTeETD:2JI1wfXOnIFLNSGMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBKVC14IIDyc4R2[3Srb36gdJJmcW6ldXLheIVlKG[xcjCxJIhzKHC{aX;yJJRwKEySUz3zeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjCxPEBpenNiYomgSWxKW0FuIFnDOVAhRSB\|LkWg{txONg>?	M2fl[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES3NlU6Lz5{NEC0O\|I2QTxxYU6=
BMDC	NEfxbWVCdnSraX7mcIFudWG2b4L5JIF{e2G7		M3vBWlEhcHJ?		NFW5R5NCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKEN3N1LMM\|YhdW:3c3WgRm1FSyClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKEmOLUGyJJA1OCCycn;keYN1cW:wIIDy[Ylv[3WkYYTl[EBnd3JiMTDodkBxemmxcjD0c{BNWFNvc4TpcZVt[XSrb36gcYVie3W{ZXSgZYZ1\XJiMUigbJJ{KGK7IFXMTXNCNCCLQ{WwJF0hPSEQvF2u	M{nGTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES3NlU6Lz5{NEC0O\|I2QTxxYU6=
HEK-293	MnG1SpVv[3Srb36gZZN{[Xl?				MXjJcohq[mm2aX;uJI9nKFKLUELLJIlvKFCjbULDV2s1NXO2aX31cIF1\WRiSFXLMVI6OyClZXzsd{BwfmW{LXX4dJJme3OrbnegWGxTOiCjc4Pld5Nm\CCjczDJUFghe2WlcnX0bY9vNCCLQ{WwJF0hPi5\|MTFOwG0v	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzFyOUi2O{c,OjdzMEm4Olc9N2F-
BMDC	Moq1RY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?		NGPDZYUyKGi{		MnP1RY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBEPTeETD:2JI1wfXOnIFLNSGMh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBVVk[jbIDoZUBxem:mdXP0bY9vKHC{ZXnuZ5Vj[XSnZDDmc5IhOSCqcjDwdolweiC2bzDMVHMue3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOThiaILzJIJ6KEWOSWPBMEBKSzVyIE2gO{42KM7:TT6=	NWDnXI1rRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFczPTlpPkK0NFQ4OjV7PD;hQi=>
macrophage-like cell	MkniRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?		NYTJeJJvOzBibXnudy=>		Mm\mRY51cWmwZnzhcY1ifG:{eTDhZ5Rqfmm2eTDpckBpfW2jbjDIUE03OCCmZYLpeoVlKG2jY4LvdIhi\2VvbHnr[UBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFzQV{1qdmS3Y3XkJHRPTmGucHjhJJBzd2S3Y4Tpc44hfHKnYYTl[EA{OCCvaX7zJIJm\m:{ZTDMVHMhe3SrbYXsZZRqd25ibXXhd5Vz\WRiYX\0[ZIhOjRiaILzJIJ6KEWOSWPBMEBKSzVyIE2gPE43KM7:TT6=	NVXa[mo{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4NVExQDlpPkKzPFEyODh7PD;hQi=>
WS	NIDvOFJHfW6ldHnvckBie3OjeR?=	NVizOmxvOi53IIXN			NEiyfndKdmirYnn0bY9vKG:oIHHubZNwdXmlaX6tbY5lfWOnZDDQN\|gu[WyyaHGgZYN1cX[jdHnvckBqdiCqdX3hckBpfW2jbjDUSXJVNWmvbX;yeIFtcXOnZDDXV{Bk\WyuczDhd5Nme3OnZDDhd{BJW1B{NzDwbI9{eGixconsZZRqd25iYYSgNk42KHWP	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ3OUi3NUc,OTd4NUm4O\|E9N2F-
WS	MnjxSpVv[3Srb36gZZN{[Xl?				MWfJcohq[mm2aX;uJI9nKE2NMjDt[YRq[XSnZDDIV3AzPyCyaH;zdIhwenmuYYTpc44hcW5iaX3tc5J1[Wyrc3XkJHdUKGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDGMYFkfGmwIIP0doV{eyCoaXLy[ZM>	NGnDNZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m2OFc5OCd-MUe5OlQ4QDB:L3G+
WS	MmDiSpVv[3Srb36gZZN{[Xl?				M3zWR2lvcGmkaYTpc44hd2ZicEO4JI1m\GmjdHXkJG1MOiCjY4TpeoF1cW:wIHnuJHdUKGOnbHzz	M1yxSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OU[0O\|gxLz5zN{m2OFc5ODxxYU6=
A673	M1[3[JFJXFNiYYPzZZk>				M1yze5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	NHP0cGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NEX4b5FyUFSVIHHzd4F6				MYDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	Mmr2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	M4DQb5FJXFNiYYPzZZk>				NETlZWdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	NX7M[HRPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	MWrxTHRUKGG\|c3H5				NY\McJM5eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	NGjLeGw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	NEPJTYpyUFSVIHHzd4F6				NE\a[VhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStNVIh[2WubIO=	M2PnOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	NH65cIJyUFSVIHHzd4F6				Mn;sdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NEXOXZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	NIrWcJNyUFSVIHHzd4F6				MU\xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MoT6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	M1rheZFJXFNiYYPzZZk>				M4\ZcpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	phospho-p38 / p38 ; p-ASK1 / ASK1 / P-JNK / p-MKK4 / p-ERK ; phospho-MK2(T334) / phospho-HSP27(S82) / phospho-Akt(T308) / phospho-Akt(S473)	25747578 24082073 21737674
Immunofluorescence	dsRNA / hnRNP A1	25747578
Growth inhibition assay	Cell viability	23001390

In vivo

SB203580 protects pig myocardium against ischemic injury in an in vivo model. ^[4]SB203580 is effective to prevent and treat the disease in MRL/lpr mice model of Systemic lupus erythematosus (SLE). ^[5]

Protocol (from reference)

Kinase Assay: ^[1]	Cellular receptor kinase phosphorylation assay : 4 μg of sheep anti-PKBα is immobilized on 25 μL of protein G-Sepharose overnight (or 1.5 hours) and washed in Buffer A (50 mm Tris, pH 7.5, 1 mm EDTA, 1 mm EGTA, 0.5 mm Na₃VO₄, 0.1% β-mercaptoethanol, 1% Triton X-100, 50 mm sodium fluoride, 5 mm sodium pyrophosphate, 0.1 mm phenylmethylsulfonyl fluoride, 1 μg/mL aprotinin, pepstatin, leupeptin, and 1 μm microcystin). The immobilized anti-PKB is then incubated with 0.5 ml of lysate (from 5 × 10⁶ cells) for 1.5 hours and washed three times in 0.5 mL of Buffer A supplemented with 0.5 m NaCl, two times in 0.5 mL of Buffer B (50 mm Tris-HCl, pH 7.5, 0.03% (w/v) Brij-35, 0.1 mm EGTA, and 0.1% β-mercaptoethanol), and twice with 100 μl of assay dilution buffer; 5× assay dilution buffer is 100 mm MOPS, pH 7.2, 125 mm β-glycerophosphate, 25 mm EGTA, 5 mm sodium orthovanadate, 5 mm DTT. To the PKB enzyme immune complex is added 10 μL of assay dilution buffer, 40 μm protein kinase A inhibitor peptide, 100 μm PKB-specific substrate peptide, and 10 μCi of [γ-³²P]ATP, all made up in assay dilution buffer. The reaction is incubated for 20 minutes at room temperature with shaking, then samples are pulse spun, and 40 μL of reaction volume are removed into another tube to which is added 20 μL of 40% trichloroacetic acid to stop the reaction. This is mixed and incubated for 5 minutes at room temperature, and 40 μL is transferred onto P81 phosphocellulose paper and allowed to bind for 30 seconds. The P81 piece is washed three times in 0.75% phosphoric acid then in acetone at room temperature. γ-³²P incorporation is then measured by scintillation counting.
Cell Research: ^[1]	Cell lines: CT6 cell , BA/F3 F7 cell Concentrations: 0–30 μM Incubation Time: 1 hour Method: CT6 cell and BA/F3 F7 cell are rested by washing three times in RPMI and culturing overnight in RPMI, 5% fetal calf serum in the absence of growth factor, antibiotics, or β-mercaptoethanol supplements. 2–5 × 10⁶ rested CT6 cells are resuspended in 2 mL of RPMI, 5% fetal calf serum and preincubated with SB203580 or vehicle control as indicated in figure legends. Cells are then stimulated with 20 ng/ml recombinant human IL-2 for 5 minutes at 37 °C and pelleted in a minifuge for 30 seconds, medium is aspirated, and the pellet is lysed in the appropriate buffer. BA/F3 cells stably expressing deletion mutants of IL-2 receptor β chain are maintained in glutamine containing RPMI further supplemented with 5% fetal calf serum and 0.2 μg/mL G418. The cells are then washed extensively, rested overnight, and washed again before activating with IL-2; such cell preparations are >90% T cells. Cellular proliferation assays are performed by measurement of [³H]thymidine incorporation.
Animal Research: ^[5]	Animal Models: Systemic lupus erythematosus (SLE) are established in female MRL/lpr mice and female C57BL/6 mice Dosages: 0.1 M/day Administration: Orally administered

References

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 4% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300 Tween 80	5mg/mL

Chemical Information

Molecular Weight	377.43
Formula	C₂₁H₁₆FN₃OS
CAS No.	152121-47-6
Storage	3 years -20°C(in the dark) powder
Smiles	CS(=O)C1=CC=C(C=C1)C2=NC(=C(N2)C3=CC=NC=C3)C4=CC=C(C=C4)F

Download Adezmapimod (SB203580) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):